RXFP1

(redirected from LGR7)

RXFP1

A gene on chromosome 4q32.1 that encodes a transmembrane G protein-coupled receptor for relaxins. Relaxin binding may also activate a tyrosine kinase pathway that inhibits the activity of a phosphodiesterase that degrades cAMP.
References in periodicals archive ?
TEL-AVIV, Israel -- Compugen (NASDAQ:CGEN) announced today that CGEN-25009, a novel peptide that previously demonstrated the ability to activate the Relaxin receptor LGR7 (RXFP1) in cell based assays, has shown positive therapeutic effects in an animal model of pulmonary fibrosis.
Known to activate the LGR7 and LGR8 GPCR receptors, the currently recognized diverse and vital roles of Relaxin include anti-fibrotic activity, homeostatic roles in reproductive health, fertility and ageing, as well as the exhibition of therapeutic properties in various pathophysiological conditions such as infertility, pregnancy and labor complications, cardiovascular diseases, inflammatory disorders, wound healing and fibrotic diseases.
The three novel peptides, CGEN-25009, 25010 and 25011, were predicted in silico through the use of Compugen's GPCR Peptide Discovery Platform and were then shown to activate the GPCRs LGR7 (RXFP1) and LGR8 (RXFP2).
In these experiments, the activation of the GPCRs LGR7 and LGR8 was further confirmed and additional information obtained regarding the activity of these novel molecules.
INSL3 interacts with a receptor called LGR8 and has been shown to be critical to testicular descent, while RLN3 interacts with a related receptor called LGR7, which has been implicated in mammary gland and nipple development.